about
Clinical management of grade III oligodendrogliomaCisplatinum and BCNU chemotherapy in primary glioblastoma patients.Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience.Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.Natural history and management of brainstem gliomas in adults. A retrospective Italian study.Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia Hospitals.Molecular markers of gliomas: a clinical approach.Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experienceIntracerebral haemorrhage in primary and metastatic brain tumours.Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.Safety of bevacizumab in patients with malignant gliomas: a systematic review.Update on treatment strategies for anaplastic glioma: a review of literature.Short course radiotherapy concomitant with temozolomide in GBM patients: a phase II study.Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.Hidden reality: sexual sphere in brain tumor patients.Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes.Caring for Brain Tumour Patients: Psychological reactions after bereavement.Cognitive strategies and quality of life of patients with high-grade glioma.Characterization of an established human, malignant, glioblastoma cell line (GBM) and its response to conventional drugs.Reversible Valproate Induced Pisa Syndrome and Parkinsonism in a Neuro-Oncology Patient with Depression and Epilepsy.Herpes simplex encephalitis in glioma patients: a challenging diagnosis.Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience.Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.Acute late-onset encephalopathy after radiotherapy: an unusual life-threatening complication.Effects of thalidomide on parameters involved in angiogenesis: an in vitro study.Recurrent brain tumour: the impact of illness on patient's life.Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report.Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments.Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells.Psychological features and quality of life in 50 adult patients with epilepsy and their caregivers from the Lecco epilepsy center, Italy.Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF.Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience.
P50
Q26801254-91AE5D66-CEF4-4255-A76A-CA76F2BB6C92Q33383259-9B631F8F-6762-4A37-BE1F-F2A152DD6A25Q33396889-2924F167-D2E0-42FE-8FF3-D518291A8229Q34505227-428E0523-79D9-44B9-A497-BFDDAE5C5558Q34753614-AA7DCA0A-9F0F-401E-8C25-A72F3163A5C1Q36388025-48F528BD-4720-436E-83F6-99BE4762D176Q36523374-D9F19F50-8AF0-4895-BBBB-17AC6369ECC0Q36935024-35DBE43B-BDCD-4FEC-AA93-02279AF8AC6CQ37238955-646ECCC2-67CC-4729-97E7-CE8E7BD2631DQ37699429-09C14911-5EC8-46CE-9346-96CC774E867AQ38166676-6B8E71E1-D4E7-492B-A92E-3A6C8AAB696EQ38214573-A9A9BC4B-9D84-4F6A-88E8-841ACBDE4BC1Q38679196-0AB733BD-17E6-4D1E-BFE2-9E3D98FEA6C9Q39100186-D6E93DEA-0B8F-40E6-9D26-BCD4A48E9D1CQ39588097-A7ECA219-6A43-4DD3-A898-713F2B86AE44Q40164269-6B5E1890-606B-4D17-A43D-382F64EDEA39Q40708205-AA0DA8B8-F966-4933-8DA3-649C386E01B1Q41243313-1BC8250A-C626-4B7B-A902-29AA2AC54923Q41502787-3FB9DA0A-4D98-4407-928A-C62C9FA1A6D7Q41880316-02D80671-104D-4A40-94AB-228B88096715Q42213188-FF3FE549-0599-46C3-8F54-862F3EA40312Q43145540-F3640630-C4B9-43A6-BB97-345A47692A7AQ43709460-D652AD5B-762E-4F5E-A586-88F53D34E7DEQ43759714-49BDCC00-EB5D-4F3C-91B7-3D7CFE4AFAD6Q43837753-03814B2E-5950-4002-BF35-83CA874BFA68Q44092540-0FF8DAE5-39C3-4B68-9F62-BA39DE08B9F6Q44616966-CEFDF74E-24F7-40DB-A732-7AFE2F5683C6Q44617218-C7DD8A50-A940-46A8-920C-3BAB566ADBFFQ44766648-6C2A7E5B-9061-4C6D-963A-09BCBA310C1FQ44999721-C898D6EB-9A8B-41ED-A3CE-717CE5296708Q46101385-4A1C060D-89EF-43E6-8D63-C57174B74C45Q46494188-9C2143DE-346A-41BA-AE74-3019EB78DEC1Q46519045-613F4469-5097-420D-A3F9-81819A7F1F5CQ46746449-783CF73B-3E66-493E-9ED2-BAC1A5537647Q46800607-B62ACA20-F550-4D31-AE32-B29818A713EEQ47150660-35E5CD2D-8BC4-4967-8565-1414C56956ECQ47425824-919DB2D7-78B3-453A-BA38-ADFA8B5582BEQ47740517-7D43F79F-B5C2-4D77-84BC-82B73903CFC2Q48095420-D02BFDFB-654F-4FFB-9744-D409580AFC51Q48112036-2812AAB3-8F74-4D52-A7DE-621EE90F22CB
P50
description
researcher
@en
wetenschapper
@nl
name
A Silvani
@en
A Silvani
@nl
type
label
A Silvani
@en
A Silvani
@nl
prefLabel
A Silvani
@en
A Silvani
@nl
P106
P31
P496
0000-0002-4791-1042